Alnylam Pharmaceuticals Inc
(NAS:ALNY)
$
267.47
-15.68 (-5.54%)
Market Cap: 35.71 Bil
Enterprise Value: 33.97 Bil
PE Ratio: 73.08
PB Ratio: 33.19
GF Score: 73/100 Alnylam Pharmaceuticals Inc at Evercore ISI HealthCONx Virtual Conference Transcript
Nov 30, 2021 / 02:40PM GMT
Release Date Price:
$183.8
(+1.69%)
Maneka Mirchandaney
Evercore ISI Institutional Equities, Research Division - Analyst
Awesome. Hi, everyone. This is Maneka Mirchandaney from the Evercore ISI biotech team. Very, very thrilled to be here with Alnylam for our next fireside chat at a very exciting time for the company. From the team, we've got Yvonne Greenstreet, who's current President and COO and incoming CEO. So thank you for joining.
Questions & Answers
Maneka Mirchandaney
Evercore ISI Institutional Equities, Research Division - Analyst
And Yvonne, to start, it must be such an exciting time for you. Also, I just want to say how awesome it is to have another female CEO at a leading biotech. But maybe to start, just give us a quick sense for what you've been focused on at Alnylam since you joined in 2016.
Yvonne L. Greenstreet
Alnylam Pharmaceuticals, Inc. - President, COO & Director
Yes, that's great. Thanks, Maneka. And look, it's a pleasure to be here, and thank you so much for having me. It is a real honor to be taking over as
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot